Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) CEO Brian Culley Purchases 15,000 Shares

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) CEO Brian Culley purchased 15,000 shares of Lineage Cell Therapeutics stock in a transaction dated Thursday, March 12th. The stock was bought at an average price of $1.62 per share, for a total transaction of $24,300.00. Following the completion of the transaction, the chief executive officer directly owned 255,516 shares in the company, valued at $413,935.92. The trade was a 6.24% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Lineage Cell Therapeutics Stock Down 5.7%

NYSEAMERICAN LCTX traded down $0.10 on Thursday, reaching $1.59. The company had a trading volume of 1,433,015 shares, compared to its average volume of 1,151,963. Lineage Cell Therapeutics, Inc. has a 52 week low of $0.37 and a 52 week high of $2.09. The stock’s 50 day moving average is $1.73 and its 200-day moving average is $1.66. The stock has a market cap of $394.81 million, a price-to-earnings ratio of -5.66 and a beta of 1.74.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last issued its earnings results on Thursday, March 5th. The company reported $0.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.07. The firm had revenue of $6.61 million for the quarter, compared to analysts’ expectations of $1.96 million. Lineage Cell Therapeutics had a negative return on equity of 76.13% and a negative net margin of 436.47%. As a group, analysts forecast that Lineage Cell Therapeutics, Inc. will post -0.12 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. D. Boral Capital boosted their price objective on shares of Lineage Cell Therapeutics from $2.00 to $3.00 and gave the company a “buy” rating in a report on Friday, March 6th. HC Wainwright reissued a “buy” rating on shares of Lineage Cell Therapeutics in a research report on Friday, March 6th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $5.00.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of LCTX. Royal Bank of Canada raised its holdings in Lineage Cell Therapeutics by 1,578.9% during the 1st quarter. Royal Bank of Canada now owns 528,656 shares of the company’s stock worth $237,000 after buying an additional 497,168 shares during the period. Rhumbline Advisers increased its position in shares of Lineage Cell Therapeutics by 9.9% during the first quarter. Rhumbline Advisers now owns 201,447 shares of the company’s stock worth $91,000 after acquiring an additional 18,092 shares in the last quarter. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Lineage Cell Therapeutics during the second quarter worth $75,000. XTX Topco Ltd raised its holdings in shares of Lineage Cell Therapeutics by 117.8% during the second quarter. XTX Topco Ltd now owns 94,054 shares of the company’s stock worth $85,000 after acquiring an additional 50,876 shares during the period. Finally, Jump Financial LLC bought a new stake in Lineage Cell Therapeutics in the 2nd quarter valued at $28,000. 62.47% of the stock is currently owned by institutional investors and hedge funds.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.